Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03280277 · ClinicalTrials.gov registry record · Early Phase 1
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer
A Early Phase 1 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT03280277: Clinical Trial Early Phase 1 study, sponsored by OHSU Knight Cancer Institute.
NCT03280277 is a Early Phase 1 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 2 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03280277, a Early Phase 1 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well ferumoxytol-enhanced magnetic resonance imaging (MRI) works in imaging lymph nodes in patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Ferumoxytol is a form of very small iron particles that are taken up by cells in normal lymph nodes and may work better in imaging patients with rectal cancer when given with MRI.
Primary Outcome
Assessed by successful accrual objectively, as a percentage of all subjects enrolled. Accrual success will be measured in binary fashion; successful accrual is considered a patient that enrolls and completes the entire trial. All other eligible patients will be considered an accrual failure. Practical feasibility will be considered a success if greater than 50%.
Interventions
- DRUG Ferumoxytol
- PROCEDURE Contrast-enhanced Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-04-27 |
| Est. Completion | 2021-08-26 |
| Phase | Early Phase 1 |
Why NCT03280277 stopped before completion
NCT03280277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Ferumoxytol is the first listed.
NCT03280277 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03280277 about?
NCT03280277 is a clinical study titled "Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer". This pilot clinical trial studies how well ferumoxytol-enhanced magnetic resonance imaging (MRI) works in imaging lymph nodes in patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Ferumoxytol is a form of very small iron particles th...
What is the current status of trial NCT03280277?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2018-04-27. Estimated completion is 2021-08-26.
What interventions are being tested in trial NCT03280277?
The interventions under investigation include: Ferumoxytol (DRUG), Contrast-enhanced Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT03280277?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03280277's enrollment target sits among peer trials
2 1973rd of 2000 higher than 16 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI